Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients

Background: Selective laser trabeculoplasty (SLT) is an effective long-term option for the treatment of open-angle glaucoma. Objectives: To investigate the real-world efficacy and safety of SLT with the Zeiss VISULAS green laser in medically treated primary open-angle glaucoma (POAG). Design: Retros...

Full description

Saved in:
Bibliographic Details
Main Authors: Brian Church, Pierre Wassermann
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Ophthalmology
Online Access:https://doi.org/10.1177/25158414241302891
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850246382848311296
author Brian Church
Pierre Wassermann
author_facet Brian Church
Pierre Wassermann
author_sort Brian Church
collection DOAJ
description Background: Selective laser trabeculoplasty (SLT) is an effective long-term option for the treatment of open-angle glaucoma. Objectives: To investigate the real-world efficacy and safety of SLT with the Zeiss VISULAS green laser in medically treated primary open-angle glaucoma (POAG). Design: Retrospective, single-center study. Methods: POAG patients ⩾18 years of age on at least one antiglaucoma medication prior to the procedure, who underwent SLT with the Zeiss VISULAS green laser (Carl Zeiss Meditec, Jena, Germany). Medications were terminated or reinstated at subsequent follow-ups depending on the intraocular pressure (IOP) control. The primary efficacy outcome measures were mean reduction in glaucoma medications and mean reduction in IOP at 3, 6, and 12 months compared to baseline. Safety outcomes were intra- or post-procedural complications. Results: One hundred fifty-six eyes of 156 patients, aged 66.5 ± 13.2 years, were recruited. The mean number of medications was reduced from 2.3 ± 1.0 at baseline to 0.8 ± 1.1 and 0.8 ± 1.2 at 3- and 6 months, respectively ( p  < 0.001). Despite the reduction of medications, the mean IOP (mmHg) was reduced from 16.6 ± 3.10 at baseline to 15.4 ± 3.82 at 3 months ( n  = 156) and 15.1 ± 3.30 at 6 months ( n  = 140) ( p  < 0.001). IOP reduction ⩾20% was observed in 28.8% of patients at 3 months and 27.9% of patients at 6 months. In the 12-month follow-up group ( n  = 22), mean medications and IOP (mmHg) at baseline were 2.3 ± 0.9 and 16.0 ± 2.80, respectively, which decreased to 0.9 ± 1.1 ( p  < 0.001) and 14.5 ± 1.92 ( p  = 0.103), respectively. At 3- and 6-month post-procedure, 59.6% of patients and 60% of patients, respectively, were medication-free compared to none at baseline. At 6 months, 69.3% of patients maintained IOP lower than or equal to pre-procedure IOP on fewer medications compared to baseline. No vision-threatening intra- or post-procedure complications were noted. Conclusion: SLT with the Zeiss VISULAS green laser resulted in a clinically and statistically significant reduction in number of medications needed for IOP control. The procedure had a good safety profile similar to that described in the literature for SLT, with no vision-threatening complications.
format Article
id doaj-art-c701dcc9f0334619a26d3491cf9b29f4
institution OA Journals
issn 2515-8414
language English
publishDate 2024-12-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Ophthalmology
spelling doaj-art-c701dcc9f0334619a26d3491cf9b29f42025-08-20T01:59:13ZengSAGE PublishingTherapeutic Advances in Ophthalmology2515-84142024-12-011610.1177/25158414241302891Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patientsBrian ChurchPierre WassermannBackground: Selective laser trabeculoplasty (SLT) is an effective long-term option for the treatment of open-angle glaucoma. Objectives: To investigate the real-world efficacy and safety of SLT with the Zeiss VISULAS green laser in medically treated primary open-angle glaucoma (POAG). Design: Retrospective, single-center study. Methods: POAG patients ⩾18 years of age on at least one antiglaucoma medication prior to the procedure, who underwent SLT with the Zeiss VISULAS green laser (Carl Zeiss Meditec, Jena, Germany). Medications were terminated or reinstated at subsequent follow-ups depending on the intraocular pressure (IOP) control. The primary efficacy outcome measures were mean reduction in glaucoma medications and mean reduction in IOP at 3, 6, and 12 months compared to baseline. Safety outcomes were intra- or post-procedural complications. Results: One hundred fifty-six eyes of 156 patients, aged 66.5 ± 13.2 years, were recruited. The mean number of medications was reduced from 2.3 ± 1.0 at baseline to 0.8 ± 1.1 and 0.8 ± 1.2 at 3- and 6 months, respectively ( p  < 0.001). Despite the reduction of medications, the mean IOP (mmHg) was reduced from 16.6 ± 3.10 at baseline to 15.4 ± 3.82 at 3 months ( n  = 156) and 15.1 ± 3.30 at 6 months ( n  = 140) ( p  < 0.001). IOP reduction ⩾20% was observed in 28.8% of patients at 3 months and 27.9% of patients at 6 months. In the 12-month follow-up group ( n  = 22), mean medications and IOP (mmHg) at baseline were 2.3 ± 0.9 and 16.0 ± 2.80, respectively, which decreased to 0.9 ± 1.1 ( p  < 0.001) and 14.5 ± 1.92 ( p  = 0.103), respectively. At 3- and 6-month post-procedure, 59.6% of patients and 60% of patients, respectively, were medication-free compared to none at baseline. At 6 months, 69.3% of patients maintained IOP lower than or equal to pre-procedure IOP on fewer medications compared to baseline. No vision-threatening intra- or post-procedure complications were noted. Conclusion: SLT with the Zeiss VISULAS green laser resulted in a clinically and statistically significant reduction in number of medications needed for IOP control. The procedure had a good safety profile similar to that described in the literature for SLT, with no vision-threatening complications.https://doi.org/10.1177/25158414241302891
spellingShingle Brian Church
Pierre Wassermann
Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
Therapeutic Advances in Ophthalmology
title Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
title_full Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
title_fullStr Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
title_full_unstemmed Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
title_short Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients
title_sort real world results of the zeiss selective laser trabeculoplasty in adult south african primary open angle glaucoma patients
url https://doi.org/10.1177/25158414241302891
work_keys_str_mv AT brianchurch realworldresultsofthezeissselectivelasertrabeculoplastyinadultsouthafricanprimaryopenangleglaucomapatients
AT pierrewassermann realworldresultsofthezeissselectivelasertrabeculoplastyinadultsouthafricanprimaryopenangleglaucomapatients